[D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats

Background and AimsHepatic ischemia–reperfusion injury (IRI) is a common phenomenon that occurs after liver transplantation and liver tumor surgery. It can cause liver dysfunction and recovery failure after liver surgery, even leading to acute liver failure. Our aim is to investigate the protective...

Full description

Bibliographic Details
Main Authors: Jueying Liu, Yuan Wang, Qianling Pan, Xueqing Chen, Yifeng Qu, Hao Zhu, Li Zheng, Yinghui Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Surgery
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2022.839296/full
_version_ 1817992604358279168
author Jueying Liu
Yuan Wang
Qianling Pan
Xueqing Chen
Yifeng Qu
Hao Zhu
Li Zheng
Yinghui Fan
author_facet Jueying Liu
Yuan Wang
Qianling Pan
Xueqing Chen
Yifeng Qu
Hao Zhu
Li Zheng
Yinghui Fan
author_sort Jueying Liu
collection DOAJ
description Background and AimsHepatic ischemia–reperfusion injury (IRI) is a common phenomenon that occurs after liver transplantation and liver tumor surgery. It can cause liver dysfunction and recovery failure after liver surgery, even leading to acute liver failure. Our aim is to investigate the protective effect and related potential mechanism of [D-Ala2, D-Leu5] enkephalin (DADLE) treatment on hepatic IRI in cirrhotic livers of rats.MethodsThe models of liver cirrhosis and hepatic IRI were established with male Sprague–Dawley rats. DADLE at a dose series of 0.5, 1, or 5 mg·kg−1 was injected intravenously to rats 10 min prior hepatic ischemia, followed by a 6- h reperfusion. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), histological changes, and liver cell apoptosis were used to assess liver IRI. The optimal dose of DADLE was assessed by using the Suzuki score and ALT and AST levels. We repeated the hepatic IRI procedure on the optimal dose of the DADLE group and the delta opioid receptor (DOR) antagonist natrindole hydrochloride (NTD) injection group. Serum ALT and AST levels, histological staining, hepatic apoptosis, and serum levels of tumor necrosis factor alpha (TNF-α) and interleukin 1 β (IL-1β) were measured. The expression of protein kinase B (Akt) and its downstream proteins were evaluated by using quantitative real-time polymerase chain action (qRT-PCR) and Western blotting.ResultsCompared with the control group, DADLE treatment at a dose of 5 mg·kg−1 reduced the Suzuki score (mean: 5.8, range: 5.0–6.6 vs. mean: 8.0, range: 7.0–8.9), the ALT level (134.3 ± 44.7 vs. 247.8 ± 104.6), and the AST (297.1 ± 112.7 vs. 660.8 ± 104.3) level. DOR antagonist NTD aggravated hepatic IRI. Compared with the control group, DADLE treatment decreased the number of apoptosis cells and microphages and neutrophils, increased the expression of Akt and its mRNA to much higher levels, and upregulated the mRNA and protein expression of Bcl-2 and Bcl-2-associated death promoter (BAD).ConclusionDADLE treatment at a dose of 5 mg·kg−1 injected intravenously 10 min prior hepatic ischemia could contain rats’ hepatic IRI by activating DOR in cirrhotic livers. The effects of DADLE could be offset by NTD. The potential molecular mechanism seems to be involved in the phosphatidylinositol-3-kinase (PI3K)/Akt pathway.
first_indexed 2024-04-14T01:28:58Z
format Article
id doaj.art-46365c107d1f4c2ebbe0b74e8da4ad8d
institution Directory Open Access Journal
issn 2296-875X
language English
last_indexed 2024-04-14T01:28:58Z
publishDate 2022-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Surgery
spelling doaj.art-46365c107d1f4c2ebbe0b74e8da4ad8d2022-12-22T02:20:17ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2022-05-01910.3389/fsurg.2022.839296839296[D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic RatsJueying LiuYuan WangQianling PanXueqing ChenYifeng QuHao ZhuLi ZhengYinghui FanBackground and AimsHepatic ischemia–reperfusion injury (IRI) is a common phenomenon that occurs after liver transplantation and liver tumor surgery. It can cause liver dysfunction and recovery failure after liver surgery, even leading to acute liver failure. Our aim is to investigate the protective effect and related potential mechanism of [D-Ala2, D-Leu5] enkephalin (DADLE) treatment on hepatic IRI in cirrhotic livers of rats.MethodsThe models of liver cirrhosis and hepatic IRI were established with male Sprague–Dawley rats. DADLE at a dose series of 0.5, 1, or 5 mg·kg−1 was injected intravenously to rats 10 min prior hepatic ischemia, followed by a 6- h reperfusion. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), histological changes, and liver cell apoptosis were used to assess liver IRI. The optimal dose of DADLE was assessed by using the Suzuki score and ALT and AST levels. We repeated the hepatic IRI procedure on the optimal dose of the DADLE group and the delta opioid receptor (DOR) antagonist natrindole hydrochloride (NTD) injection group. Serum ALT and AST levels, histological staining, hepatic apoptosis, and serum levels of tumor necrosis factor alpha (TNF-α) and interleukin 1 β (IL-1β) were measured. The expression of protein kinase B (Akt) and its downstream proteins were evaluated by using quantitative real-time polymerase chain action (qRT-PCR) and Western blotting.ResultsCompared with the control group, DADLE treatment at a dose of 5 mg·kg−1 reduced the Suzuki score (mean: 5.8, range: 5.0–6.6 vs. mean: 8.0, range: 7.0–8.9), the ALT level (134.3 ± 44.7 vs. 247.8 ± 104.6), and the AST (297.1 ± 112.7 vs. 660.8 ± 104.3) level. DOR antagonist NTD aggravated hepatic IRI. Compared with the control group, DADLE treatment decreased the number of apoptosis cells and microphages and neutrophils, increased the expression of Akt and its mRNA to much higher levels, and upregulated the mRNA and protein expression of Bcl-2 and Bcl-2-associated death promoter (BAD).ConclusionDADLE treatment at a dose of 5 mg·kg−1 injected intravenously 10 min prior hepatic ischemia could contain rats’ hepatic IRI by activating DOR in cirrhotic livers. The effects of DADLE could be offset by NTD. The potential molecular mechanism seems to be involved in the phosphatidylinositol-3-kinase (PI3K)/Akt pathway.https://www.frontiersin.org/articles/10.3389/fsurg.2022.839296/fullhepatic ischemia–reperfusion injurydelta opioid receptorphosphatidylinositol-3-kinase (PI3K)/Akt pathwaycirrhotic liversratsDADLE
spellingShingle Jueying Liu
Yuan Wang
Qianling Pan
Xueqing Chen
Yifeng Qu
Hao Zhu
Li Zheng
Yinghui Fan
[D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats
Frontiers in Surgery
hepatic ischemia–reperfusion injury
delta opioid receptor
phosphatidylinositol-3-kinase (PI3K)/Akt pathway
cirrhotic livers
rats
DADLE
title [D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats
title_full [D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats
title_fullStr [D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats
title_full_unstemmed [D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats
title_short [D-Ala2, D-Leu5] Enkephalin Attenuates Hepatic Ischemia–Reperfusion Injury in Cirrhotic Rats
title_sort d ala2 d leu5 enkephalin attenuates hepatic ischemia reperfusion injury in cirrhotic rats
topic hepatic ischemia–reperfusion injury
delta opioid receptor
phosphatidylinositol-3-kinase (PI3K)/Akt pathway
cirrhotic livers
rats
DADLE
url https://www.frontiersin.org/articles/10.3389/fsurg.2022.839296/full
work_keys_str_mv AT jueyingliu dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT yuanwang dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT qianlingpan dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT xueqingchen dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT yifengqu dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT haozhu dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT lizheng dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats
AT yinghuifan dala2dleu5enkephalinattenuateshepaticischemiareperfusioninjuryincirrhoticrats